A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Soo Youn Lee; Myung Hyun Nam; Soo Kim June; Jong Won Kim

doi:10.3346/jkms.2007.22.3.557

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Soo Youn Lee, Myung Hyun Nam, Soo Kim June, Jong Won Kim

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

Original language	English
Pages (from-to)	557-559
Number of pages	3
Journal	Journal of Korean medical science
Volume	22
Issue number	3
DOIs	https://doi.org/10.3346/jkms.2007.22.3.557
Publication status	Published - 2007
Externally published	Yes

Keywords

Cytochrome P-450 CYP2C9
Pharmacogenetics
Polymorphism
Prothrombin time
Warfarin

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.3346/jkms.2007.22.3.557

Cite this

@article{6a1c0af277e9433ca595812fa3820176,

title = "A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement",

abstract = "We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.",

keywords = "Cytochrome P-450 CYP2C9, Pharmacogenetics, Polymorphism, Prothrombin time, Warfarin",

author = "Lee, {Soo Youn} and Nam, {Myung Hyun} and June, {Soo Kim} and Kim, {Jong Won}",

year = "2007",

doi = "10.3346/jkms.2007.22.3.557",

language = "English",

volume = "22",

pages = "557--559",

journal = "Journal of Korean medical science",

issn = "1011-8934",

publisher = "Korean Academy of Medical Science",

number = "3",

}

TY - JOUR

T1 - A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

AU - Lee, Soo Youn

AU - Nam, Myung Hyun

AU - June, Soo Kim

AU - Kim, Jong Won

PY - 2007

Y1 - 2007

N2 - We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

AB - We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

KW - Cytochrome P-450 CYP2C9

KW - Pharmacogenetics

KW - Polymorphism

KW - Prothrombin time

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=34447116378&partnerID=8YFLogxK

U2 - 10.3346/jkms.2007.22.3.557

DO - 10.3346/jkms.2007.22.3.557

M3 - Article

C2 - 17596671

AN - SCOPUS:34447116378

SN - 1011-8934

VL - 22

SP - 557

EP - 559

JO - Journal of Korean medical science

JF - Journal of Korean medical science

IS - 3

ER -

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this